Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio clinico del sistema Nectero EAST (stAAAble)

23 settembre 2026 aggiornato da: Nectero Medical, Inc.

Sperimentazione clinica controllata randomizzata (RCT) del sistema Nectero EAST per la stabilizzazione degli aneurismi dell'aorta addominale di piccole e medie dimensioni (AAA): valutazione dell'efficacia.

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

400

Fase

  • Fase 2
  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Reclutamento
        • Prince of Wales Private Hospital- POW Vascular Institute
        • Investigatore principale:
          • Ramon Varcoe
        • Contatto:
      • Auckland, Nuova Zelanda, 1023
        • Reclutamento
        • Auckland City Hospital
        • Contatto:
        • Investigatore principale:
          • Andrew Holden, A/Prof
    • Arizona
      • Scottsdale, Arizona, Stati Uniti, 85258
        • Reclutamento
        • Honor Health Scottsdale Shea Medical Center
        • Investigatore principale:
          • Hasan Aldailami, MD
        • Contatto:
          • HonorHealth Cardiovascular Research
          • Numero di telefono: 480-323-1046
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Attivo, non reclutante
        • University of Colorado
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Reclutamento
        • Medstar Washington Hospital Center
        • Investigatore principale:
          • Steven Abramowitz, MD
        • Contatto:
        • Contatto:
    • Florida
    • Georgia
      • Augusta, Georgia, Stati Uniti, 30912
        • Reclutamento
        • Medical College of Georgia
        • Investigatore principale:
          • William Jordan, MD
        • Contatto:
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago
        • Contatto:
        • Investigatore principale:
          • Ross Milner, MD
      • Elk Grove, Illinois, Stati Uniti, 60007
        • Non ancora reclutamento
        • Ascension Alexian Brothers
        • Investigatore principale:
          • Jack Chamberlin, MD
    • Maine
      • Scarborough, Maine, Stati Uniti, 04074
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Massachusetts General Hospital
        • Investigatore principale:
          • Nikolaos Zacharias, MD
        • Contatto:
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Beth Israel Deaconess Medical Center
        • Investigatore principale:
          • Marc Schermerhorn, MD
        • Contatto:
        • Contatto:
      • Worcester, Massachusetts, Stati Uniti, 01655
        • Reclutamento
        • University of Massachusetts
        • Contatto:
        • Investigatore principale:
          • Andres Schanzer, MD
    • Michigan
      • Royal Oak, Michigan, Stati Uniti, 48073
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine
        • Investigatore principale:
          • Luis Sanchez, MD
        • Contatto:
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University of Nebraska Medical Center
        • Investigatore principale:
          • Jonathan Thompson, MD
        • Contatto:
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03766
        • Reclutamento
        • Dartmouth Hitchcock Medical Center
        • Investigatore principale:
          • Rebecca Scully, MD
        • Contatto:
    • New York
      • Rochester, New York, Stati Uniti, 14642
      • Stony Brook, New York, Stati Uniti, 11794
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center
        • Investigatore principale:
          • Chandler Long, MD
        • Contatto:
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45219
      • Cleveland, Ohio, Stati Uniti, 44106
        • Reclutamento
        • University Hospitals Cleveland
        • Investigatore principale:
          • Jae Cho, MD
        • Contatto:
      • Cleveland, Ohio, Stati Uniti, 44195
        • Reclutamento
        • Cleveland Clinic
        • Investigatore principale:
          • Francis Caputo, MD
        • Contatto:
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • The Ohio State University Wexner Medical Center
        • Contatto:
        • Investigatore principale:
          • Kristine Orion, MD
      • Columbus, Ohio, Stati Uniti, 43214
        • Reclutamento
        • Ohio Health Riverside
        • Investigatore principale:
          • Joseph Campbell, MD
        • Contatto:
    • Oklahoma
      • Tulsa, Oklahoma, Stati Uniti, 74104
        • Reclutamento
        • Oklahoma Heart Institute
        • Investigatore principale:
          • Julia Chen, MD
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Reclutamento
        • Portland VA Medical Center
        • Investigatore principale:
          • Matthew Koopmann, MD
        • Contatto:
    • Pennsylvania
      • Bethlehem, Pennsylvania, Stati Uniti, 18015
        • Reclutamento
        • St. Luke's University Health Network
        • Investigatore principale:
          • Sharvil Sheth, MD
        • Contatto:
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Hospital of the University of Pennsylvania
        • Contatto:
        • Investigatore principale:
          • Grace Wang, MD
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Reclutamento
        • Jefferson Clinical Research Institute
        • Contatto:
        • Investigatore principale:
          • Michael Nooromid, MD
      • Pittsburgh, Pennsylvania, Stati Uniti, 15219
        • Reclutamento
        • University of Pittsburgh Medical Center
        • Contatto:
        • Investigatore principale:
          • Raymond Eid, MD
    • South Carolina
    • South Dakota
      • Sioux Falls, South Dakota, Stati Uniti, 57108
        • Reclutamento
        • North Central Heart - A Division of Avera Heart Hospital
        • Investigatore principale:
          • Michael Bacharach, MD
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
      • Nashville, Tennessee, Stati Uniti, 37212
        • Non ancora reclutamento
        • VA Tennessee Valley Healthcare System
        • Investigatore principale:
          • John Curci, MD
        • Contatto:
    • Texas
      • Houston, Texas, Stati Uniti, 77004
      • Plano, Texas, Stati Uniti, 75093
        • Reclutamento
        • Baylor Scott & White Medical Center
        • Investigatore principale:
          • William Shutze, MD
        • Contatto:
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84132
        • Reclutamento
        • University of Utah Hospital
        • Contatto:
        • Investigatore principale:
          • Cali Johnson, MD
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • Inova Fairfax Medical Campus Inova Health Systems
        • Contatto:
        • Investigatore principale:
          • Kendal Endicott, MD
      • Norfolk, Virginia, Stati Uniti, 23507
        • Reclutamento
        • Sentara Health
        • Investigatore principale:
          • David Dexter, MD
        • Contatto:
    • Washington
      • Seattle, Washington, Stati Uniti, 98104
        • Reclutamento
        • University of Washington at Harborview Medical Center
        • Contatto:
        • Investigatore principale:
          • Benjamin Starnes, MD
    • Wisconsin
      • Green Bay, Wisconsin, Stati Uniti, 54301

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 21 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).
  2. Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
  3. Infrarenal atherosclerotic fusiform abdominal aortic aneurysm from 3.5 cm to 5.0 cm (male) and 3.5 cm to 4.5 cm (female).
  4. Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.
  5. Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 130 mm.
  6. Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.
  7. Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.
  8. Subject has > three-year life expectancy.
  9. Subject is able and willing to comply with all required follow-up clinic visits including CT scans (pre-randomization, 6, 12, 18, 24 months and annually up to 5 years) and blood draws.

Exclusion Criteria:

  1. Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.
  2. Subject has a symptomatic infrarenal abdominal aortic aneurysm.
  3. Subject has a mycotic or infected aneurysm.
  4. Subject has current vascular injury due to trauma.
  5. Subject's aneurysm is thoracic, suprarenal or juxtarenal.
  6. Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
  7. Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus.
  8. Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.
  9. Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure.
  10. Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.
  11. Subject has undergone other major surgery within the 30 days prior to enrollment.
  12. Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
  13. Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and/or pentagalloylglucose (PGG).
  14. Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
  15. Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).
  16. Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure.
  17. Subject has active systemic infection.
  18. Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).
  19. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.
  20. Subject has dialysis dependent renal failure or baseline serum creatinine level >2.5mg/dL or eGFR < 45 mL/min/1.73m2.
  21. Subjects with aminotransferase (ALT and/or AST) which is ≥1.5x upper limit of normal (ULN) or TB that is our of normal range for the evaluating laboratory.
  22. Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.
  23. Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.
  24. Subjects with saccular AAA.
  25. Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.
  26. Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.
  27. Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR >3 for a subject on anti-coagulant therapy.
  28. Subjects with active/acute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases.
  29. Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and/or steatosis grade of S3).
  30. Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men.
  31. Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment Arm

Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.

Intervention: Drug: Stabilizer

Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.

Nessun intervento: Control Arm

Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Primary Endpoint
Lasso di tempo: 24 months

The primary endpoint is the composite of all AAA-related death, rupture and repair (open-surgical, EVAR, or clinically indicated for repair as adjudicated by a committee of clinical experts blinded to the assigned arm).

24 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Growth
Lasso di tempo: 24 months

The growth over time in aneurysm diameter based on CT core laboratory readings.

24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Daniel Clair, MD, Vanderbilt University Medical Center
  • Investigatore principale: Grace Wang, MD, University of Pennsylvania

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 ottobre 2023

Completamento primario (Stimato)

30 giugno 2028

Completamento dello studio (Stimato)

31 dicembre 2032

Date di iscrizione allo studio

Primo inviato

7 agosto 2023

Primo inviato che soddisfa i criteri di controllo qualità

14 agosto 2023

Primo Inserito (Effettivo)

21 agosto 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • EAST002

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .